suvratoxumab

Home
Ligands
suvratoxumab

GtoPdb Ligand ID: 13361

Synonyms: AR-320 | MEDI4893

Comment: Suvratoxumab is a clinical stage fully human IgG1 monoclonal antibody that prevents binding of Staphylococcus aureus alpha-toxin to its cellular receptor ADAM10 [2]. It is being developed for the prevention of nocosomial pneumonia caused by S. aureus.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

References
1. François B, Jafri HS, Chastre J, Sánchez-García M, Eggimann P, Dequin PF, Huberlant V, Viña Soria L, Boulain T, Bretonnière C et al.. (2021) Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. Lancet Infect Dis, 21 (9): 1313-1323. [PMID:33894131]
2. Oganesyan V, Peng L, Damschroder MM, Cheng L, Sadowska A, Tkaczyk C, Sellman BR, Wu H, Dall'Acqua WF. (2014) Mechanisms of neutralization of a human anti-α-toxin antibody. J Biol Chem, 289 (43): 29874-80. [PMID:25210036]

References

1. François B, Jafri HS, Chastre J, Sánchez-García M, Eggimann P, Dequin PF, Huberlant V, Viña Soria L, Boulain T, Bretonnière C et al.. (2021)
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.
Lancet Infect Dis, 21 (9): 1313-1323. [PMID:33894131]

2. Oganesyan V, Peng L, Damschroder MM, Cheng L, Sadowska A, Tkaczyk C, Sellman BR, Wu H, Dall'Acqua WF. (2014)
Mechanisms of neutralization of a human anti-α-toxin antibody.
J Biol Chem, 289 (43): 29874-80. [PMID:25210036]